Cytek Biosciences Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
CTKB$5.79-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
Cytek Biosciences, Inc
Consolidated Statements of Cash Flows
| Three months ended March 31, | ||
|---|---|---|
| (In thousands) | 2024 | 2023 |
| Cash flows from operating activities: | ||
| Net loss | $(6,169) | $(6,807) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 1,699 | 1,001 |
| Amortization of operating lease-right-of use assets | 761 | 800 |
| Stock-based compensation | 5,640 | 4,699 |
| Loss on disposal of property and equipment | 47 | — |
| Provision for credit losses | 121 | — |
| Provision for excess and obsolete inventory | 912 | 508 |
| Gain on investments, accretion, and amortization, net | (1,202) | (1,580) |
| Interest expenses for accretion of the legal settlement liabilities | 301 | 544 |
| Change in operating assets and liabilities: | ||
| Trade accounts receivable | 4,235 | 6,055 |
| Inventories | 4,773 | (3,188) |
| Prepaid expenses and other assets | (2,925) | (136) |
| Trade accounts payable | 615 | 305 |
| Accrued expenses and other liabilities | (4,599) | 1,763 |
| Legal settlement liabilities | (67) | (351) |
| Operating lease liabilities | (727) | (706) |
| Deferred revenue | 542 | (49) |
| Net cash provided by operating activities | 3,957 | 2,858 |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (77,132) | (123,239) |
| Proceeds from maturities of marketable securities | 72,000 | — |
| Purchase of property and equipment | (567) | (505) |
| Acquisition of business | — | (44,895) |
| Purchase of intangible assets | (55) | — |
| Payment for additional investment in Cytek Japan | — | (235) |
| Net cash used in investing activities | (5,754) | (168,874) |
| Cash flows from financing activities: | ||
| Repayment of loan | (139) | (146) |
| Payments for taxes related to net share settlement of equity awards | (148) | (57) |
| Proceeds from issuance of common stock under employee stock plans | 506 | 203 |
| Proceeds from line of credit | 1,394 | — |
| Net cash provided by financing activities | 1,613 | — |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,695 | (1,090) |
| Cash, cash equivalents and restricted cash: | ||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 1,511 | (167,106) |
| Cash, cash equivalents and restricted cash at beginning of period | 167,630 | 299,500 |
| Cash, cash equivalents and restricted cash at end of period | $169,141 | $132,394 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for taxes | $— | $93 |
| Non-cash investing and financing activities: | ||
| Fixed asset purchases in accounts payable or accrued purchase at period end | $288 | $139 |
| Intangible asset in accounts payable or accrued expenses at period end | $46 | $4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.